Compare MBBC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | NSRX |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | Israel |
| Employees | 35 | 7 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 32.2M |
| IPO Year | N/A | N/A |
| Metric | MBBC | NSRX |
|---|---|---|
| Price | $14.02 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 18.3K | ★ 53.9K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $1.98 |
| 52 Week High | $15.75 | $9.99 |
| Indicator | MBBC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 48.07 |
| Support Level | $12.90 | $2.04 |
| Resistance Level | $15.57 | $3.48 |
| Average True Range (ATR) | 0.54 | 0.28 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 77.72 | 32.03 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.